Related Experiment Videos
Current staging of renal cell carcinoma
Bradley C Leibovich1, Allan J Pantuck, Matthew H T Bui
1Department of Urology, Division of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, Suite 66-118, Los Angeles, CA 90095, USA.
The Urologic Clinics of North America
|September 5, 2003
Summary
Most kidney cancers are renal cell carcinoma (RCC). This review examines current RCC staging systems and discusses adding prognostic markers for better diagnosis and treatment of kidney cancer.
Area of Science:
- Oncology
- Urologic Oncology
- Cancer Prognostics
Background:
- Renal cell carcinoma (RCC) accounts for over 80% of kidney cancers.
- A significant proportion of patients present with metastatic disease or relapse after treatment for localized RCC.
- Accurate diagnostic and prognostic information is crucial for effective patient management.
Purpose of the Study:
- To review the historical development and rationale behind current renal cell carcinoma (RCC) staging systems.
- To explore the potential of incorporating additional clinical, pathological, and molecular markers to improve RCC prognostication.
- To enhance the understanding of factors influencing the diagnosis and prognosis of kidney cancer.
Main Methods:
- Literature review of historical and current staging systems for renal cell carcinoma (RCC).
- Analysis of existing clinical, pathological, and molecular markers relevant to RCC prognosis.
- Discussion of the integration of novel markers into future staging frameworks.
Main Results:
- Current staging systems for RCC have evolved over time.
- Various clinical, pathological, and molecular factors demonstrate prognostic value in RCC.
- There is a clear need to refine staging to better predict patient outcomes.
Conclusions:
- Existing RCC staging systems provide a foundation for patient stratification.
- Integrating novel prognostic markers holds significant promise for improving the accuracy of RCC staging.
- Enhanced staging will lead to more personalized treatment strategies for kidney cancer patients.